Metyrosine treatment in a woman with chromosome 22q11.2 deletion syndrome and psychosis: a case study

被引：6

作者：

Engebretsen, Maria Hagen ^{[1
]}

Kildahl, Arvid Nikolai ^{[1
]}

Hoy, Iver Harald ^{[2
]}

Bakken, Trine Lise ^{[1
]}

机构：

[1] Oslo Univ Sykehus, Oslo, Norway

[2] Lovisenberg Hosp, Oslo, Norway

来源：

INTERNATIONAL JOURNAL OF DEVELOPMENTAL DISABILITIES | 2019年 / 65卷 / 02期

关键词：

22q11; 2 deletion Syndrome; intellectual disability; psychosis; psychotropic medication; SCHIZOPHRENIA; ADULTS; SCALE;

D O I：

10.1080/20473869.2017.1401257

中图分类号：

G76 [特殊教育];

学科分类号：

040109 ;

摘要：

Background: People with 22q11.2 deletion syndrome (DS) are assumed to be especially vulnerable to developing mental illness such as psychosis. Aim: The study was established to contribute to knowledge about metyrosine medication in patients with 22q11.2 DS and psychosis. Methods: A case study was established including a woman with intellectual disability, 22q11.2 DS, and psychosis. Metyrosine medication was implemented, as conventional anti-psychotic medication was unsuccessful. Results: Effect of metyrosine medication included both psychotic symptom relief with decreased aggressive behaviour. Adjunctive milieu therapy contributed to complience. Conclusion: For patients with 22q11.2 DS and psychosis, metyrosine medication may prove effective. However, there are significant ethical dilemmas related to metyrosine medication for psychotic symptoms.

引用

页码：116 / 121

页数：6

共 27 条

[1]

Aman MG., 1986, ABERRANT BEHAV CHECK

[2] Antipsychotic Treatment of 22q11.2 Deletion Syndrome-Related Psychoses [J].